Leksum LLC, an early-stage life sciences company based in Boston, Massachusetts, has signed an agreement with the Department of Anesthesia, Intensive Care Medicine and Pain Medicine at the Medical University of Vienna, with Phoenestra GmbH as a co-signatory, to conduct preparatory work leading up to Phase I/II first-in-human clinical trials for LK-ICU. The announcement, made on October 13, 2026, marks a critical step toward testing a novel biologic therapy that could address a significant and often overlooked complication of critical care: diaphragm muscle weakness acquired during mechanical ventilation.
Preclinical studies of LK-ICU, which consists of extracellular vesicles derived from bone marrow mesenchymal stromal cells, indicate an almost complete preservation of both diaphragm muscle fiber size and function that is normally lost with mechanical ventilation. This is important because prolonged mechanical ventilation can lead to ICU-acquired weakness, a condition that extends weaning time and is estimated to impact the quality of life of hundreds of thousands of patients each year in the U.S. and Europe. By potentially preserving diaphragm integrity, LK-ICU could reduce the duration of ventilation, shorten ICU stays, and improve long-term recovery for critically ill patients.
The agreement with the Medical University of Vienna, a leading European clinical research institution, positions Leksum to leverage European clinical data to support its U.S. regulatory path. Leksum plans to start efforts under the agreement upon closing its Series A financing round. The planning phase is expected to last several months, after which the company intends to initiate Phase I/II trials. This timeline suggests that, if successful, LK-ICU could enter clinical development within a few years, offering a first-in-class approach to a condition that currently has no approved therapies.
Leksum's pipeline extends beyond LK-ICU to include other skeletal muscle conditions such as sarcopenia, cancer cachexia, and muscle loss due to the use of weight-loss drugs like GLP-1s. This broader focus on acquired muscle myopathies underscores the company's strategy to develop advanced biologic therapies for muscle-wasting conditions that affect millions worldwide. The collaboration with the Medical University of Vienna not only validates the science behind LK-ICU but also provides a pathway for efficient clinical translation.
For the critical care community, this announcement signals a potential shift in how mechanical ventilation is managed. If LK-ICU proves effective in humans, it could become a standard adjunct therapy to prevent diaphragm atrophy, reducing the burden on healthcare systems and improving patient outcomes. The involvement of Phoenestra GmbH as a co-signatory further strengthens the initiative, bringing additional expertise and resources to the preparatory work. More details about the agreement and the full announcement can be found click here. For ongoing updates, visit Leksum.
The significance of this news lies in its potential to address an unmet medical need with a novel biologic mechanism. While mechanical ventilation is lifesaving, its side effects on the diaphragm can lead to prolonged recovery and increased mortality. By targeting the underlying muscle damage, LK-ICU could transform the standard of care. The agreement also highlights the growing trend of transatlantic collaboration in life sciences, with a U.S. company leveraging European clinical infrastructure to accelerate development. As Leksum moves toward its Series A and subsequent trials, the life sciences industry will be watching closely to see if this innovative therapy can deliver on its preclinical promise.
